Improving life for cancer patients through transformative drugs

Play

News

2018/11/21

Medivir nominates MIV-828 as a candidate drug for the treatment of hematological malignancies

Read more
2018/10/26

MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2018

Read more
2018/10/19

New data from the MIV-711 phase II program will be presented at the ACR Annual Meeting on October 21

Read more

Partner with Medivir

Partnering is an important element of our business strategy. Together with our partners we have been successful in taking two products from research, through clinical development to launch on a global scale.